Dr. Jia Ruan, M.D., Ph.D.
Claim this profileNYP/Weill Cornell Medical Center
Studies Lymphoma
Studies Sézary Syndrome
6 reported clinical trials
15 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage I
CD3 positive
2Sézary Syndrome
Stage II
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Jia Ruan, M.D., Ph.D. is currently running
Lenalidomide + EPOCH Chemotherapy
for Adult T-Cell Leukemia-Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.
Recruiting1 award Phase 1
Zanubrutinib
for Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria
More about Jia Ruan, M.D., Ph.D.
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jia Ruan, M.D., Ph.D. has experience with
- Lenalidomide
- Prednisone
- Duvelisib
- Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; Vincristine Sulfate
- Nivolumab
- CC-486
Breakdown of trials Jia Ruan, M.D., Ph.D. has run
Lymphoma
Hematological Tumors
Postprandial Fullness Syndrome
Mycosis Fungoides/Sezary Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jia Ruan, M.D., Ph.D. specialize in?
Jia Ruan, M.D., Ph.D. focuses on Lymphoma and Sézary Syndrome. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage I.
Is Jia Ruan, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Jia Ruan, M.D., Ph.D. is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Jia Ruan, M.D., Ph.D. has studied deeply?
Yes, Jia Ruan, M.D., Ph.D. has studied treatments such as Lenalidomide, Prednisone, Duvelisib.
What is the best way to schedule an appointment with Jia Ruan, M.D., Ph.D.?
Apply for one of the trials that Jia Ruan, M.D., Ph.D. is conducting.
What is the office address of Jia Ruan, M.D., Ph.D.?
The office of Jia Ruan, M.D., Ph.D. is located at: NYP/Weill Cornell Medical Center, New York, New York 10065 United States. This is the address for their practice at the NYP/Weill Cornell Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.